Reduced Plasma Apelin Levels in Patients with Autistic Spectrum Disorder

Marianna Boso, Enzo Emanuele, Pierluigi Politi, Alessandro Pace, Mariarosa Arra, Stefania Ucelli di Nemi, Francesco Barale

Research output: Contribution to journalArticlepeer-review


Background: Dysregulation of the vasopressin (AVP) system has been implicated in the pathogenesis of autistic spectrum disorder (ASD). Apelin is a recently discovered neuropeptide that could counteract AVP actions and whose receptors are colocalized with vasopressin in hypothalamic magnocellular neurons. Aims of the present study were to investigate circulating levels of apelin in patients with ASD and to assess their correlation with plasma AVP concentrations. Methods: Plasma levels of apelin and AVP were measured in a total of 18 patients with ASD and 21 age- and gender-matched healthy comparison subjects. The Childhood Autism Rating Scale (CARS) was used to assess the severity of autistic symptoms. Results: Significantly reduced levels of apelin (p

Original languageEnglish
Pages (from-to)70-74
Number of pages5
JournalArchives of Medical Research
Issue number1
Publication statusPublished - Jan 2007


  • Apelin
  • Autistic spectrum disorders
  • Neuropeptides
  • Vasopressin

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Reduced Plasma Apelin Levels in Patients with Autistic Spectrum Disorder'. Together they form a unique fingerprint.

Cite this